

RESOURCES

State of the Science for Substance Use Prevention

Carlos Blanco, MD, PhD

Director

Division of Epidemiology, Services, & Prevention Research

National Institute on Drug Abuse









PRESENTER BIO

Carlos Blanco, MD, PhD



Carlos Blanco, M.D, PhD is the Director of the Division of Epidemiology, Services, and Prevention Research at the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

Dr. Blanco is a national known expert in the epidemiology and treatment of addictive disorders. Prior to joining NIDA, Dr. Blanco was Professor of Psychiatry at Columbia University Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute.

He is a graduate of Universidad Autónoma de Madrid (Spain) and completed his psychiatry residency at Columbia University, where he also completed a research fellowship.


Dr. Blanco has authored over 350 peer-reviewed publications.







State of the Science for Substance Use Prevention



Carlos Blanco, M.D., Ph.D.

Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse






What do we know?


- Treatment is not enough
- Risk factors
- Course of Disorders
- Intervention Efficacy

Cumulative Probability of treatment for SUD




Blanco et al., Drug Alcohol Depend, 2015

There are Multiple Risk Factors




3


RISK FACTORS FOR SUBSTANCE USE DISORDER



Natural course of remission for four substances




Course of relapse of smoking



Garcia-Rodriguez et al., Drug Alcohol Depend, 2013


7

Example from PROSPER Community Prevention Delivery System—Young Adult Outcomes of Middle School Programs



Note: *p<.05, RRRs=20-26% Source: R Spoth et al. *American Journal of Public Health* 2013. PROSPER vs. control differences are practically significant: For every 100 misusers in non-PROSPER communities, there would be about 20-26 fewer in PROSPER communities.


Parents who were in the SSDP intervention in childhood grow up to have children with lower youth self-reported alcohol and drug onset (ages 6 -18 years)



Areas of Opportunity

- Efficacy and effectiveness research to examine intervention effects on initiation and progression of use
- Strategies to reduce harm
- Interventions to advance health equity and address upstream social determinants of health
- Research that develops and tests strategies, frameworks or tools to **disseminate**, **implement**, and **sustain** evidence-based interventions
- Fundamental science for intervention development

TARGET SYSTEMS





Challenge: limited prevention funding




Solution: fund research grounded in strong partnerships with end-users to design economical and sustainable interventions


Building partnerships with stakeholders/end users

- Potential partners to facilitate transition form research to practice:
 - ACF/ASPE potential funding through Family First Preventive Services Act
 - HRSA/FQHCs informed HEAL FY23 RFA
 - SAMHSA block grants, discretionary funds, Prevention Technology Transfer Centers; Office of Prevention Innovation
 - Department of Justice
 - CMS/CMMI
 - Department of Education
 - Indian Health Service
 - CDC
 - Others?

Traditional View of Innovation: Top Down



LHS: Dialogue and Iteration



Cumulative Probability of treatment for SUD

